Search

Search Constraints

You searched for: Author/Creator Oyanagi, Jun

Search Results

3. CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50. Issue 1 (27th November 2020)

5. IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer. Issue 4 (22nd March 2019)

6. Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer. (19th November 2019)

7. Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor‐tyrosine kinase inhibitors in patients with EGFR‐mutant non‐small cell lung cancer. Issue 10 (30th August 2019)

8. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. (January 2020)

9. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. (June 2019)